Neurothera Labs Engages bullVestor for Investor Relations Activities

April 23, 2026 – TheNewswire - Vancouver, British Columbia, Canada - Neurothera Labs Inc. (TSXV: NTLX) ( “ Neurothera ” or the “ Company ”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), today announced that it has engaged bullVestor Median GmbH (“ bullVestor ”) pursuant to an investor relations agreement dated April 23, 2026 for assistance with its investor awareness marketing campaign. bullVestor provides marketing and investor relations services and will assist the Company in enhancing its visibility with potential investors by providing, among other services, content creation management, keyword optimization, ad groups and display ads, project management, and media distribution for a total cost of euro 300,000 for a 6-month period commencing on or about the date on which the TSX Venture Exchange (“ TSXV ”) approves the engagement (the “ TSXV Approval ”). Pursuant to the agreement respecting the engagement, euro 150,000 is payable within seven days following the date of the TSXV Approval, with the remaining euro 150,000 being payable within 45 days following the date of the TSXV Approval. bullVestor is an arm's length party from the Company and principally operates out of Austria. As of the date of this press release, to the knowledge of the Company, neither bullVestor nor any of its directors and officers own any interest, directly or indirectly, in the securities of the Company. bullVestor's engagement is subject to approval of the TSXV.